KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity: 2018-2024

Historic Common Equity for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $455.8 million.

  • Castle Biosciences' Common Equity rose 5.89% to $467.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $467.0 million, marking a year-over-year increase of 5.89%. This contributed to the annual value of $455.8 million for FY2024, which is 16.50% up from last year.
  • Latest data reveals that Castle Biosciences reported Common Equity of $455.8 million as of FY2024, which was up 16.50% from $391.3 million recorded in FY2023.
  • In the past 5 years, Castle Biosciences' Common Equity registered a high of $455.8 million during FY2024, and its lowest value of $391.3 million during FY2023.
  • Over the past 3 years, Castle Biosciences' median Common Equity value was $399.1 million (recorded in 2022), while the average stood at $415.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 388.40% in 2020, then decreased by 3.06% in 2022.
  • Yearly analysis of 5 years shows Castle Biosciences' Common Equity stood at $415.7 million in 2020, then decreased by 0.95% to $411.7 million in 2021, then decreased by 3.06% to $399.1 million in 2022, then dropped by 1.97% to $391.3 million in 2023, then increased by 16.50% to $455.8 million in 2024.